Assessment of the effectiveness of Budesonide MMX for active, mild-to-moderate ulcerative colitis in the Polish sub-group of the CORE Practice prospective multi-centre observational study.

Introduction: Budesonide MMX is approved for induction of remission in mild-to-moderate active ulcerative colitis (UC) in adults in whom 5-ASA is not sufficient. There is a lack of data on its effectiveness and safety in clinical practice.

Material And Methods: The CORE Practice study was a multi-centre prospective, observational study of mild-to-moderate UC-patients treated with Budesonide MMX 9 mg for up to 8 weeks (induction).

Does a Provider in Triage and Rapid Medical Evaluation Help With Left Without Being Seen Rates and ED Crowding?

Introduction: Attempting to reduce ED crowding, the ED team at a rural academic medical center and specialty hospital implemented rapid medical evaluation (RME) with and without a provider in triage (PIT). The purpose of this performance improvement project was to explore how these interventions affected crowding metrics of door-to-disposition time, ED length of stay (LOS), and left without being seen (LWBS) rates for all patients.

Methods: Using a prospective 2-group design, the pre-RME population served as the historical control group, and postintervention groups included both RME with and without PIT.